Prothena Corporation plc (PRTA)

Market Cap	680.91M
Revenue (ttm)	135.16M
Net Income (ttm)	-122.31M
Shares Out	53.83M
EPS (ttm)	-2.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	390,383
Open	13.27
Previous Close	13.34
Day's Range	12.57 - 13.30
52-Week Range	11.70 - 26.36
Beta	-0.03
Analysts	Buy
Price Target	54.57 (+331.38%)
Earnings Date	May 7, 2025

About PRTA

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline includes birtamimab, an investigational humanized antibody, which in phase 3 clinical trial to treat patients with AL amyloidosis; and Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson’s disease and other syn...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 163
• Stock Exchange: NASDAQ
• Ticker Symbol: PRTA
• Website: https://www.prothena.com

Financial Performance

In 2024, Prothena Corporation's revenue was $135.16 million, an increase of 47.92% compared to the previous year's $91.37 million. Losses were -$122.31 million, -16.81% less than in 2023.

Analyst Forecast

According to 9 analysts, the average rating for PRTA stock is "Buy." The 12-month stock price forecast is $54.57, which is an increase of 331.38% from the latest price.

Price Target

$54.57

(331.38% upside)

Analyst Consensus: Buy